A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study Background: The efficacy and tolerability of the regimen containing paclitaxel and cisplatin (TP) in the neo-adjuvant treatment of locally advanced squamous cell cervical cancer are unknown. The TIP regimen (TP plus ifosfamide) showed high efficacy but high toxicity and it is used as an internal control. and median age (42 years/45 years). The optimal response rate in the TP group was 25%, 95% confidence interval (CI) = 16% to 37% and 43%, 95% CI = 31% to 55% in the TIP group. Grades 3-4 leukopenia (6%/53%) and neutropenia (26%/76%) were significantly more frequent on TIP.
introduction
The concurrent use of cisplatin-based chemotherapy and radiation therapy has been the standard of care of patients with locally advanced cervical cancer since the 1999 National Cancer Institute Alert strongly supported its use in all patients with cancer requiring radiation [1] . Neo-adjuvant chemotherapy followed by surgery is a completely different therapeutic approach that seems to offer a few specific advantages over chemoradiation such as a better potential activity against micrometastastic disease, a debulking effect improving subsequent surgical outcome, less toxicity, and an easier management of salvage therapy. A recently published systematic review and meta-analysis of individual patient data included five randomized trials enrolling 872 patients randomly assigned to neo-adjuvant chemotherapy followed by surgery (6radiotherapy) or radical radiotherapy [2, 3] . A survival analysis showed that neo-adjuvant therapy improved 2-year and 5-year survival by 8%-14% and 12%-16%, respectively, depending by stage, as compared with radical radiotherapy. Yet, neo-adjuvant chemotherapy remains controversial as these trials and the meta-analysis were planned before concurrent chemoradiation became the standard treatment. A face to face comparison of chemoadjuvant therapy followed by surgery versus concurrent chemoradiation is still lacking as this original article question is being addressed by a still ongoing trial sponsored by EORTC (55994). Selecting the most efficient cytotoxic regimen for neo-adjuvant chemotherapy is another major issue. Results from our previous trial revealed that the paclitaxel, ifosfamide, and cisplatin (TIP) regimen was superior with regard to response rates to the ifosfamide and cisplatin (IP) doublet, although the triplet combination was burdened with high toxicity [4] . In that trial, we also showed that the achievement of an optimal response [i.e. complete response (CR) or partial response (PR) with microinvasive residual lesion (<3 mm) on histology] was a significant prognostic factor and a surrogate end point for survival. On the basis of these reports, the current randomized phase II trial was aimed at assessing the two-drug regimen of cisplatin and paclitaxel in terms of optimal response rate and toxicity in the treatment of locally advanced squamous cell cervical carcinoma. The TIP arm was used as an internal control.
patients and methods
eligibility and randomization
Pretreatment evaluation included history, physical examination, biopsy, complete blood analysis, and chest X ray. Tumor imaging by means of magnetic resonance imaging (MRI) and urography was done to determine the extent of disease and to assess ureteral morphology. Cisplatin 75 mg/m 2 was administered at 1 mg per min infusion rate.
Posthydration: 2.5 l of normal saline added with 10 mEq/l of potassium chloride and 10 mEq/l of MgSO 4 given >6 h. In PT regimen, the two drugs (paclitaxel and cisplatin) were given as in TIP regimen and, in both arms, treatment was administered every 3 weeks for a total of three courses.
treatment modifications
Complete blood counts were carried out weekly or more often in case of toxicity, while evaluation of renal and hepatic function was repeated before each cycle. Treatment administration was based on evaluation of blood cell count before the start of each cycle. Treatment was administered if absolute granulocyte count was ‡1500/ll and platelets count was ‡100 000/ll. Treatment was to be delayed week to week until minimum hematological parameters were met. After two consecutive treatment delays, on the basis of physician judgment, treatment was either interrupted or continued with the support of recombinant human granulocyte colony-stimulating factor in instances of persistent grade 4 myelotoxicity. In this latter case, ifosfamide was to be reduced to 25% of the initial dose. Delays were not permitted other than for documented toxicity.
treatment after neo-adjuvant chemotherapy and evaluation of response Tumor extension was assessed clinically and by MRI after three courses and all patients deemed operable underwent radical hysterectomy [6] and pelvic lymphadenectomy within 3 or 4 weeks after the administration of the third cycle. Patients with inoperable tumors because of progression after adjuvant chemotherapy were offered radical radiotherapy. Clinical objective tumor responses were determined according to the Response Evaluation Criteria in Solid Tumors criteria [7] . Pathological responses were defined as follows: optimal pathologic response (OPR) included a complete disappearance of tumor in the cervix with negative nodes (CR) or a residual disease with <3 mm stromal invasion including in situ carcinoma (PR1); suboptimal response (SOR) consisted of persistent residual disease with >3 mm stromal invasion on surgical specimen (PR2). Women with positive nodes, parametrial involvement, cut-through or SOR or optimal response but still with positive nodes underwent further treatment (external beam irradiation or radiochemotherapy). Patients who achieved a CR or PR received two further courses of chemotherapy after surgery with the same agents used in neo-adjuvant treatment. In this case, the cisplatin dosage was reduced at 50 mg/m 2 .
toxicity measure
All patients who had received at least one cycle were assessable. Toxic effects were assessed using the National Cancer Institute Common Toxicity Criteria (version 2.0).
follow-up procedures
Patients were monitored for assessment of disease status 1 month after the end of treatment and every 3 months for the first 3 years and every 6 months thereafter. Monitoring comprised pelvic examination and vaginal cytology; MRI or computed tomography scan of the pelvis and abdomen and chest X-ray were carried out every 6 months for 2 years and once a year thereafter.
statistical methods
This was a randomized multicentric phase II study aimed at evaluating the activity and toxicity of TP in neo-adjuvant setting for patients with locally advanced squamous cell cervical cancer, with add-on randomization to improve patient comparability (TIP arm). An OPR rate of <22% would not merit additional study. Given the assumption that a clinical relevant OPR rate is 40%, the TP arm was planned to have 69 patients to exclude an OPR <22% with a one-sided type I error of 5% and to provide 95% statistical power to find an OPR of at least 40% [8] . The lower threshold was set at 22% to be similar to the OPR rate gained by the IP doublet in our previous study (23%) [4] .
The primary activity parameter was OPR rate and for consistency with other studies such rate was presented with 95% confidence intervals (CIs). Secondary end points were overall survival (OS) and disease-free survival.
Response to chemotherapy treatments was compared using a multiple logistic regression model with a dichotomous dependent variable: optimal pathological response (CR+PR1) versus suboptimal pathological response (PR2) and clinically stable (no change) or progressive disease. The response odds ratio (OR) was defined as the odds of achieving optimal response in the TIP group divided by the odds of achieving optimal response in the TP Annals of Oncology original article group. As a consequence, an OR above unity indicates that the TIP treatment is associated with an increase in the probability of optimal response over TP. The OR computed was adjusted for differences in stage of disease and age.
Comparisons of the rates of optimal response and maximum grade of toxicity between the two arms were carried out by use of a two-sided v 2 test or a two-sided Fisher's exact test if the number of patients in a given category was five or fewer. OS was defined as the time from random treatment allocation to death from any cause; patients known to be still alive at the time of analysis were censored at the time of their last contact. Progression-free survival was defined as the time from randomization to first appearance of progressive disease or death from any cause; patients known to be alive and without progressive disease at the time of analysis were censored at the time of their last contact.
We compared Kaplan-Meier curves for OS and progression-free survival using the log-rank test [9] . Proportional hazards regression model was also used for progression-free and OS to estimate the treatment relative hazards ratio (HR), while adjusting for other pretreatment factors (stage and age) [10] . All analyses were done on an intention-to-treat basis except for the analyses of toxicity. The latter analyses were restricted to all patients who received at least one cycle of allocated treatment. All P values are two sided. Analyses were carried out using SAS software Version 9.0.
results
From October 2000 to January 2004, 154 patients were entered onto SNAP02 randomized trial from six centers in Italy. Of the 154 patients, 80 were assigned to receive the TP combination regimen, whereas 74 patients received the TIP combination regimen ( Figure 1) .
As shown in Table 1 , the distributions of pretreatment characteristics such as age, WHO performance status, FIGO stage, tumor grade, and proportion of patients with radiological lymph node involvement at randomization were balanced between the treatment arms.
compliance and toxicity
We collected full details about the TP and TIP treatments received by 79 (99%) and 73 (99%) patients, respectively. Similar proportion of patients in each arm completed the planned treatment (96% TP, 97% TIP), but 5% of patients did so with some dose adjustment or delay in the TP arm compared with 22% of patients in the TIP group.
No differences emerged between the median cisplatin and paclitaxel dose given per cycle in the TP arm and in the Table 2 .
Hematological toxicity was relevant in both arms. TIP was associated with significant higher rates of grade 3 or 4 original article Annals of Oncology hematological toxicity than TP schedule (78% versus 29%; P < 0.0001). Nausea and vomiting were similar in both arms. As expected, neurosensory symptoms were frequent but mild in both groups. There were eight drug-related serious adverse events (AEs) that required hospitalization, five in the TIP arm (three cases of pancytopenia and two of anemia) and three in the TP arm (two cases of neutropenic fever and one of urinary tract infection with fever). These eight serious AEs caused an overall hospital stay of 56 days, 38 for the patients on TIP and 18 for the patients on TP. In this study population, we recorded no toxic deaths.
effect of treatment on tumor response
One hundred and forty-five of 152 assessable patients (95%) were assessed for clinical or pathologic response (75 in the TP arm, 70 in the TIP) (Figure 1) .
The proportion of patients who underwent surgical interventions after at least one course of chemotherapy was 95% (94% in the TP group and 97% in the TIP group). Seven patients did not undergo the planned surgery (five in the TP group and two in the TIP group) because of disease progression (five patients), patient refusal (one patient), or worsening of clinical conditions (one patient). Of the 145 operated patients, three underwent a type IV Piver-Rutledge radical hysterectomy, 103 underwent a Meigs-Magara or type III Piver-Rutledge radical hysterectomy, 32 underwent a Wertheim or type II Piver-Rutledge radical hysterectomy. Three women underwent exploratory laparatomy only and a hysterectomy was not carried out because of local extension of disease and bulky lymph node metastases. no significant differences in the surgical approach emerged between the two treatment groups
The optimal response rate (CR + PR1) in the TP group was 25% (95% CI 16.0% to 36.7%) and it was 43% (95% CI 31.1% to 55.2%) in the TIP group (Table 3) . The overall optimal response OR showed a significant benefit of TIP over TP in a logistic multivariate analysis which contained grade and age as covariates [OR 2.3 (95% CI 1.1-4.7, P = 0.027)]. The percentage of patients with stage Ib2 who had an optimal response was 24% in the TP arm and 53% in the TIP arm. In patients with stage IIa-b, the optimal response rate was 27% in both groups.
Out of the 131 patients who achieved a CR or PR and therefore were candidate for two courses of TIP or TP after surgery, only 70 (53%) received further chemotherapy as scheduled. This was largely due to a change in clinical management of the patients who achieved suboptimal PR. In fact, 21 (16%) and 37 (28%) PR2 patients underwent radiotherapy or radiotherapy and chemotherapy as further therapy after surgery in TIP and TP groups, respectively. Only 2 (4%) of the 49 patients who achieved optimal response underwent postoperative radiation therapy.
effect of treatment on progression-free and OS
At a median follow-up of 43 months (25th-75th percentiles 38-46 months), tumor has recurred in 45 patients (30%) and 30 (19%) women have so far died (19 TP, 11 TIP). The sites of recurrence are listed in Table 4 . Kaplan-Meier progression-free survival curve is shown in Figure 2 . Those patients on TIP experienced a failure rate 33% less than those on TP but this difference was not statistically significant (HR = 0.67; 95% CI 0.37-1.21; P = 0.18). Figure 3 depicts the OS curves for the two treatments. Comparison of the survival curves showed a not statistically significant HR of 0.56 in favor of TIP (95% CI 0.26-1.17; P = 0.123). The difference in the overall death rates between treatment groups remained practically unchanged, and Annals of Oncology original article still statistically not significant, when stage and age at randomization were taken into account in a Cox regression analysis. We were unable to formally assess if optimal response (CR + PR1) is a prognostic factor for survival since none out of the 49 patients who achieved an optimal response died during study follow up interval.
discussion
This phase II randomized trial failed to achieve its primary objective of demonstrating that the OPR rate in the patients using the TP regimen was statistically >22% which was set as the prespecified threshold for clinical efficacy. In a previous trial, we had compared the TIP regimen with another doublet (IP) and we showed that the TIP chemotherapy was significantly more active than the IP regimen, though more toxic [4] . The TP regimen was chosen for this trial in the hope to maintain the activity of the TIP regimen while improving its safety profile. Unfortunately, the performance of the TP regimen was comparable to the performance of the IP doublet that in our previous trial showed an OPR of 23% in a similar clinical setting [4] . Such indirect comparison seems tenable since the TIP regimen yielded very similar results in terms of optimal response rate in the two trials. In fact, the OPR of 43% observed in this trial compares with the 48% observed in our previous trial. TIP regimen confirmed also its substantial toxicity with hematologic toxicity being more common and more severe compared with the TP arm. Dose adjustments and delays were also more frequent with the TIP schedule although median doses of cisplatin and paclitaxel were similar between the two arms. Although other chemotherapy combinations have shown activity in carcinoma of the uterine cervix [11] , this study confirms that the TIP schedule is one of the most active neo-adjuvant chemotherapeutic regimens. Although this was a noncomparative phase II trial, a logistic multivariate analysis showed that TIP can more than double the odds of attaining an overall optimal response versus TP [OR 2.3 (95% CI 1.1-4.7, P = 0.027)] while the HR for death, though not statistically significant, was almost halved [HR 0.56 (95% CI 0.26-1.17; P = 0.123)]. An important tenet of neo-adjuvant clinical trials is that tumor response, as a surrogate end point, should be correlated with patient survival. This trial was not designed and sized to TP, paclitaxel and cisplatin; TIP, paclitaxel, ifosfamide, and cisplatin; CR, complete disappearance of tumour in the cervix with negative nodes; PR1, residual disease with <3 mm stromal invasion including in situ carcinoma; PR2, persistent residual disease with >3 mm stromal invasion on surgical specimen; SD, stable disease; PD, progression disease. original article Annals of Oncology address such an issue, but our data compare favorably with our previous experience that showed OPR to be an independent predictor for survival and they further credit the predictive role of optimal response with statistical robustness. Neo-adjuvant chemotherapy was able to shrink tumors and downstage disease, allowing for surgical resection in >90% of the patients with marginally resectable or unresectable cancers. OS of the study population was satisfactory and most of the patients achieving optimal response (47 of 49) were spared radiotherapy. In light of this, neo-adjuvant chemotherapy followed by definitive surgical local treatment seems to prove to be a valid alternative to the standard concomitant chemoradiation approach for locally advanced cervical cancer, especially considering that an increasing number of versatile robotic surgical platforms are becoming available worldwide. Notwithstanding, a formal comparison of neo-adjuvant chemotherapy plus surgery and concomitant chemoradiation in randomized phase III trials is still lacking and eagerly awaited by oncogynecologists. Such a randomized trial has been already launched by EORTC (protocol 55994), but the accrual rate is low and results seem to be years in the future. Moreover, such trial is comparing concurrent chemoradiation with a generic platinum-based neo-adjuvant chemotherapy. Considering the great differences we observed in the activity of different platinum-based regimens, we wonder whether this ongoing protocol should be amended to include, at least in its final accrual phase, a subgroup of patients treated with TIP. 
